Dyadic International Inc. (NASDAQ: DYAI) Starts Presentation at NobleCon16
Dyadic International (NASDAQ: DYAI) is a global biotechnology company developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, monoclonal antibodies,…







